SEMAFOLLOWNCT07423481
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
StatusRecruiting
PhaseNot specified
SponsorNantes University Hospital
Primary completion (estimated)
At risk: Primary completion moved 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 1, 2026 to Oct 21, 2026
- Primary and study completion dates: Jul 1, 2027 to Jul 21, 2027
- Site details revised
- Notable Start date: Jun 1, 2026 to Oct 1, 2026
- Eligibility criteria expanded, about 3 words
- Primary and study completion pushed from Mar 1, 2027 to Jul 1, 2027
- Collaborators: details revised at 1 of 1 entry
- Minor Secondary endpoints: details revised at 3 of 3 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Describe weight changes during the follow-up period according to patient characteristics.
Timeframe: Baseline
Secondary (3)
Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.
Compare the profiles of responders and non-responders
Describe weight change according to different subpopulations.
Arms and interventions
SEMAFOLLOW study population
Patient agreeing to participate in the SEMAFOLLOW study.
Other: SEMAFOLLOW questionnaire
Sites
1 site in 1 country
- Nantes university hospitalNantes, France